Transcatheter Aortic Valve Replacement in Special Populations

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Aortic stenosis is a prevalent cardiovascular disease.
• Transcatheter aortic valve replacement (TAVR) has transformed treatment since its FDA approval in 2011.
• Seminal TAVR trials did not adequately represent certain high-risk or special populations.

Purpose of the Study:

• To provide a comprehensive overview of TAVR utilization in special populations.
• To discuss data and considerations for TAVR in patients excluded from initial trials.
• To evaluate TAVR feasibility in nonagenarians, patients with renal dysfunction, thrombocytopenia, bicuspid aortic valves, rheumatic valve disease, failed bioprostheses, and mixed valve disease.

Main Methods:

• Review of existing data and clinical considerations.
• Analysis of TAVR outcomes in specific high-risk patient cohorts.
• Synthesis of evidence from observational studies and valve-in-valve interventions.

Main Results:

• TAVR is a feasible therapeutic strategy in high-risk and special populations.
• TAVR offers significant mortality benefits in these groups.
• TAVR leads to substantial improvements in quality of life for selected patients.

Conclusions:

• TAVR is an effective treatment option for complex aortic stenosis patients.
• Further randomized controlled trials are recommended to validate findings in high-risk populations.
• TAVR expands treatment options for patients previously considered inoperable or high-risk.